
Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Wild Chamomile (Matricaria chamomilla) contains over 120 secondary metabolites including the key bioactive compound apigenin, which inhibits COX-2 and iNOS enzymes while suppressing NF-κB, p38, and JNK inflammatory signaling pathways. The herb's α-bisabolol and essential oils provide complementary anti-inflammatory effects, achieving 73.3% inhibition of mast cell degranulation at 300 mg/kg doses.

Reported Benefits (Provisional)
Origin & History

Wild Chamomile (Matricaria chamomilla), commonly known as German chamomile, is a daisy-like flowering herb native to Europe and Western Asia. Widely cultivated and revered, it has a long history of use in traditional medicine for its calming, digestive, and healing properties. This versatile herb is a cornerstone in functional nutrition, supporting nervous system balance, gastrointestinal comfort, and immune resilience.
Research Narrative (Provisional)
Extensive research, including studies indexed on PubMed, validates Wild Chamomile's sedative and anxiolytic effects, primarily attributed to compounds like apigenin. Further studies on ScienceDirect and ResearchGate highlight its essential oils' digestive benefits, anti-inflammatory actions, and significant antioxidant potential.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
- Phytochemicals/Bioactives: Bisabolol (sesquiterpene alcohol), Apigenin (flavonoid), other Polyphenols, other Flavonoids, Essential Oils (e.g., chamazulene, spiroether)
Reported Mechanism (Provisional)
Wild Chamomile's primary bioactive compounds apigenin, quercetin, and α-bisabolol work through multiple molecular pathways to achieve therapeutic effects. Apigenin inhibits cyclooxygenase-2 (COX-2) and inducible nitric oxide synthase (iNOS) enzymes while suppressing pro-inflammatory NF-κB, p38, and JNK signaling cascades. The essential oil component α-bisabolol and its oxides provide additional anti-inflammatory activity by reducing prostaglandin E2 (PGE2) levels by 50% and may inhibit fungal growth through ergosterol biosynthesis blockade.
Clinical Narrative (Provisional)
Current clinical evidence for wild chamomile is primarily based on in vitro and animal studies rather than large-scale human trials. Research demonstrates that chamomile achieves TNF-α inhibition with an IC₅₀ value of 26 µg/mL when combined with other extracts versus 98 µg/mL for chamomile alone. One human study confirmed that chamomile flavonoids and essential oils penetrate below the skin surface into deeper tissue layers, supporting topical applications. However, comprehensive clinical data with specific patient populations and quantified outcomes remains limited, indicating need for more robust human trials.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.







